BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17445657)

  • 1. EPCA-2: a highly specific serum marker for prostate cancer.
    Leman ES; Cannon GW; Trock BJ; Sokoll LJ; Chan DW; Mangold L; Partin AW; Getzenberg RH
    Urology; 2007 Apr; 69(4):714-20. PubMed ID: 17445657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Zeng G; Zhong W
    Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
    Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
    Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia.
    Zhao Z; Zeng G
    Endocr Relat Cancer; 2010 Jun; 17(2):505-12. PubMed ID: 20308359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
    Leman ES; Magheli A; Cannon GW; Mangold L; Partin AW; Getzenberg RH
    Prostate; 2009 Aug; 69(11):1188-94. PubMed ID: 19418497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
    Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
    J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB; Robson CN; Neal DE; Leung HY
    J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
    Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
    Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.